parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.09 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in basal keratinocytes	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	6 Parkinson's trials, 0 stopped	1.00
literature PubMed	27 Parkinson's papers of 5,706	0.56
pathways Reactome	7 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 2891

receipt 2899: DST in dopamine neurons, braak

power: full sample -0.07 (p 0.794, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.01 (p 0.956, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.05 (p 0.854, n 18). could be the mix.
skeptic: leave-one-out range -0.21 to +0.05, sign flips 3; without severely affected donors -0.07 (p 0.794, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DST in dopamine neurons.

case closed: nothing better to follow up.

receipt 2898: DST in oligodendrocytes, braak

power: full sample +0.41 (p 0.091, n 18), 95% CI -0.07 to +0.74. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.41 (p 0.091, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.62 (p 0.0062, n 18). not the mix.
skeptic: leave-one-out range +0.34 to +0.56, sign flips 0; without severely affected donors +0.41 (p 0.091, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DST in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts